A study to evaluate long-term safety of the experimental drug TKI258 in patients with solid tumors who received TKI258 in another study that has completed its primary objective, and who continue to be...

Mise à jour : Il y a 5 ans
Référence : EUCTR2014-000368-17

A study to evaluate long-term safety of the experimental drug TKI258 in patients with solid tumors who received TKI258 in another study that has completed its primary objective, and who continue to benefit from TKI258 treatment

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who are currently receiving treatment with single agent dovitinib within a Novartis sponsored study which has fulfilled the requirements for the primary objective


Critère d'inclusion

  • Patients with solid tumours